BIS-001ER

Small molecule

BIS-001ER is one of 4 small molecule programs targeting Focal impaired awareness seizure. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Focal Impaired Awareness SeizureActive, not recruiting

Focal Impaired Awareness SeizurePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Focal Impaired Awareness Seizure

#DrugCompanyPhaseTrials

Briviact

UCB

Approved

—2

Neurontin

VViatris Specialty LLC

Fintepla

BIS-001ER

Supernus Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Focal Impaired Awareness Seizure

NCT03474770

Clinical

Trials by Indication[1]

Focal impaired awareness seizure1 trial

BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Active, not recruiting· Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.·Phase 1/2·NCT03474770·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BIS-001ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIS-001ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIS-001ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Supernus Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Supernus Pharmaceuticals, Inc.

BIS-001ER

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Focal impaired awareness seizure1 trial

References

Drug Info

Quick Facts

Related News